ASX Runners of the Week: Argent, Peregrine, NewPeak Metals & Caspin
The Bulls N’ Bears ASX Runner of the Week is… Argent BioPharma, striking a smart licensing deal for its CannEpil epilepsy drug that wipes out a major debt overhang while retaining blue-sky through…
Read the full articleYou might also wanna read
ASX Runners of the Week: Argent, Peregrine, NewPeak Metals & Caspin
The Bulls N’ Bears ASX Runner of the Week is… Argent BioPharma, striking a smart licensing deal for its CannEpil epilepsy drug that wipes ou
BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?
Forte Biosciences announced results from its early-stage study for its investigational drug to treat an autoimmune skin condition.
Missed Out on Nvidia's Historic Run? These 2 Winners Are Just Getting Started.
Micron and Nebius still have a ton of upside compared to Nvidia.
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel
STAT+: Compass says depression drug has long-lasting benefits
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
Comments
Sign in to join the conversation.
No comments yet. Be the first.